glp-1 science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements GLP-1 increases preingestive satiation via

They are not for human consumption, not for medical or veterinary use, and not approved by the FDA or any regulatory authority

The FDA signaled new limits on non-approved compounded GLP-1 APIs being mass-marketed, and it explicitly called out Hims

With a potential OSA indication looming, how could this impact sleep apnea treatment

It is an effective medication for controlling high blood sugar levels in those with type-2 diabetes

Observational analyses and randomized clinical trials consistently report nausea, vomiting, diarrhea, constipation, and abdominal discomfort as the most common symptoms, although the distribution of events varies

The pathophysiology is unclear, but risk factors are thought to be the same as the type 1 diabetic patients who rapidly improved A1c in the Diabetes Control and Complications Trial: long duration of diabetes mellitus, long duration of poor glycemic control, worse baseline level of DR prior to treatment and magnitude of reduction in A1c after treatment